Identifying predictors of heart damage from chemotherapy in cancer patients
Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
University College, London · NCT05159479
This study is trying to find out what factors can predict heart damage in cancer patients receiving a specific type of chemotherapy for gastrointestinal cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University College, London (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT05159479 on ClinicalTrials.gov |
What this trial studies
This observational cohort study focuses on patients with gastrointestinal cancers who are receiving fluoropyrimidine-based chemotherapy. Participants will undergo a thorough cardiovascular risk assessment and will be monitored for cardiac symptoms, ECG changes, and cardiac biomarkers at various stages of their treatment. The goal is to identify robust predictors of cardiotoxicity associated with this chemotherapy regimen. By following participants throughout their treatment, the study aims to enhance understanding of how chemotherapy affects heart health.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who are consenting to receive fluoropyrimidine chemotherapy for gastrointestinal malignancies.
Not a fit: Patients under 18 or those lacking the capacity to consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and prevention strategies for heart damage in cancer patients undergoing chemotherapy.
How similar studies have performed: Other studies have explored cardiotoxicity in cancer treatments, but this specific approach to identifying predictors in gastrointestinal cancer patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 * Consented to receive fluoropyrimidine chemotherapy for GI malignancies (gastro-oesophageal, colorectal, pancreatic) * Capacity to provide consent Exclusion Criteria: * Age \<18 * Lacking capacity to consent
Where this trial is running
London
- St Bartholomews Hospital — London, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: Aderonke Abiodun
- Email: aderonketemilade.abiodun@nhs.net
- Phone: 07737138851
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiotoxicity, Gastrointestinal Neoplasms, Fluoropyrimidine, Cardio-oncology